Design a robotic surgery procedure to remove a healthy kidney from the donor using an AI guided robot.

Robotic Surgery

Robotic-assisted surgery enables you to receive sophisticated treatments with less downtime. It uses specialized technology to deliver precise care, even in hard-to-reach areas. Robotic surgery treats conditions affecting your heart, digestive system, bladder, prostate and more.

Artificial intelligence and kidney transplantation

  • Artificial intelligence and its primary subfield, machine learning, have started to gain widespread use in medicine, including the field of kidney transplantation. We made a review of the literature that used artificial intelligence techniques in kidney transplantation.
  • We located six main areas of kidney transplantation that artificial intelligence studies are focused on:
  • Radiological evaluation of the allograft, pathological evaluation including molecular evaluation of the tissue, prediction of graft survival, optimizing the dose of immunosuppression, diagnosis of rejection, and prediction of early graft function.
  • Machine learning techniques provide increased automation leading to faster evaluation and standardization, and show better performance compared to traditional statistical analysis. Artificial intelligence leads to improved computer-aided diagnostics and quantifiable personalized predictions that will improve personalized patient care.
Keywords: Artificial intelligence, Kidney transplantation, Machine learning, Neuronal networks, Deep learning, Support vector machines

Core Tip: Artificial intelligence is used in a large spectrum of areas in kidney transplantation. Developments in those areas will shape the future of medical care with faster and more standardized medical evaluations and more accurate personalized judgments.

INTRODUCTION

  • Artificial intelligence (AI) is a “buzzword” that has begun to be used increasingly in medicine, and the field of transplantation is not exempt from that. AI vests the machines with the ability to perform intelligent and cognitive tasks, spanning numerous subfields that are current and popular.
  • Machine learning (ML) is one of the most important subfields of AI and has recently seen an increase of interest in several industries, including the healthcare industry, because of advances in Big Data technology and computing power.
  • The process of ML begins with the ability of the program to observe the collected data and compare them with previous ones to find patterns and results, and then adjust itself accordingly.
  • There are a plethora of statistical-based ML algorithms that can be used in the context of three overarching categories:
  • Supervised learning, unsupervised learning, and reinforcement learning (Table ​. Supervised learning comprises learning patterns from labeled datasets and decodes the relationships between input variables (independent variables) and their known outputs (dependent variables).
  • Examples of common algorithms used for supervised learning include regression analysis [linear regression, logistic regression (LR), and non-linear regression], decision trees (DT), k-nearest neighbors, artificial neural networks (ANN), and support vector machines (SVM).
  • The proper classification of LR is context-dependent and depends on whether it is used for prediction (ML) or inferential statistics to evaluate the associations between the independent variable(s) and dependent variables (non-ML).
  • In the case of unsupervised learning the output variables are unlabeled, and this method focuses on analyzing the relationships between input variables and revealing hidden patterns that can be obtained to create new labels regarding possible outputs.
  • In this way it is possible to discover the existing patterns in the data that we are unaware of. K-means clustering is an example of the algorithms for unsupervised learning. Reinforcement learning is the most advanced category of ML.
  • In this method, a prediction model is built by gaining feedback through random trials of a vast number of possible input combinations and leveraging insight from previous iterations by grading their performance. Finally, Q-learning is an example of the algorithms for reinforcement.

Table 1

Different machine learning categories


Supervised learning
Unsupervised learning
Reinforcement learning
Dataset Labeled (input and output are known) Unlabeled (output is not known) No predefined data
Method Analyze the relation between input and output. The output is predicted based on this relation Analyze the input parameters to uncover hidden patterns. Output is predicted based on those patterns Randomly trialing a vast number of possible inputs, then comparing and grading their performance
Example Decision trees, support vector machines, neutral networks, k-nearest neighbors k-means clustering, archetype analysis Q-learning
 

METHODS

  • We used the PubMed interface (pubmed.gov) to make a query using the combination of the following two keyword groups.
  • The first group included the keywords “kidney transplant”, “renal transplant”, “kidney transplantation”, and “renal transplantation” and the second group included “artificial intelligence”, “machine learning”, “deep learning”, and “neural networks”.
  • Each keyword in the same group was combined using the logical operator “OR”, while the two groups were combined using the logical operator “AND”. We excluded the review articles and ran the query in January 2021.
  • We found 114 articles in total and manually examined them. The articles that were not directly related to kidney transplantation, dealing with other types of renal replacement therapy besides transplantation, solely using LR as the ML method, reviews, conference reports, and editorials were excluded. We also examined the references of the related articles to locate additional literature.
  • Finally, we found 64 articles that were eligible for the review.
  • We grouped the articles in the following categories: Radiological evaluation (n = 6), pathological evaluation (n = 14), prediction of graft survival (n = 16), optimizing the dose of immunosuppression (n = 7), diagnosis of rejection (n = 6), prediction of early graft function (n = 6), and others (n = 9) ).
 
 

APPLICATION OF AI IN KIDNEY TRANSPLANTATION

Radiological evaluation

  • The first paper using AI techniques for the evaluation of allografts, based on imaging techniques, was that of Hamilton et al. The authors used 99mTc-MAG3 captopril renography to evaluate the presence of renal artery stenosis in the allograft. The authors used a neural network-based classifier, and their gold standard was arteriogram. Following the training of the neural network, they found that an accuracy of 95% could be achieved.
  • Some other papers also used AI techniques for the radiological evaluation of allografts with the aim of diagnosing acute rejection. El-Baz et al investigated the early detection of acute rejection using dynamic contrast-enhanced magnetic resonance imaging (MRI).
  • The researchers automated data acquisition from the MRI using a three-step algorithmic approach and this data feed was linked to a Bayesian supervised classifier to diagnose acute rejection. The authors also studied motion correction models to account for the local motion of the kidney due to patient moving and breathing. Then, they used the perfusion curves to feed the Bayesian supervised classifier with the aim of distinguishing normal and acute rejection.
  • Three additional papers from the same group examined the utility of computer-aided diagnostic (CAD) systems for the diagnosis of acute rejection. In their first study, the authors used deep-learning algorithms, namely, ‘stacked non-negative constrained auto-encoders’, for the prediction of acute rejection.
  • Their data feed was the outcomes of diffusion-weighted MRI (DW-MRI). In their second study, in addition to DW-MRI, creatinine clearance and creatinine values were also used for the data feed of convolutional neural network (CNN) based classifiers. In both papers, the overall accuracy for correct diagnosis of acute rejection was above 90%. The authors proposed that their results demonstrated the potential of this new CAD system to reliably diagnose renal transplant rejection.
  • In a third study, they again assessed the utility of the CAD system for the diagnosis of acute rejection using DW-MRI and blood oxygen level-dependent MRI as the image-based sources. The authors also used laboratory data consisting of creatinine and creatinine clearance.
  • In addition, they utilized a deep learning-based classifier, namely, ‘stacked autoencoders’, to differentiate non-rejection from acute rejection in renal transplants. The overall accuracy of the CAD system in detection of acute rejection was around 90%.

Pathological evaluation

  • AI applications have also been used to assess allograft biopsies, where data feed for the classification algorithms was histological findings, molecular biomarkers, or a combination of the two.
  • Kazi et al used 12 histological features to train a Bayesian network with 110 transplant biopsies. Using the Bayesian network, a relatively inexperienced pathologist was able to make the correct diagnosis in 19 out of 21 cases. The researchers suggested that the integration of data with a computer can give a more consistent diagnosis of early acute rejection.
  •  In a follow-up study, the same researchers used a simple neural network for the decision process and the authors pointed out that in Bayesian networks the ‘importance’ attached to each histological feature had to be calculated and programmed into the network at the onset and because of this approach, they have the disadvantage of relative inflexibility.
  • A neural network has the potential of greater flexibility, because the process of ‘training’ a neural network would automatically calculate what ‘weight’ should be allocated to each histological feature. The authors used 12 histological features, 100 transplant biopsies (43 with definite rejection), and 25 additional cases to train a single-layer simple neural network.
  • Eventually, the network was able to correctly classify 19 out of the 21 new cases, leading to the conclusion that neural network technology can dramatically improve the accuracy in histological diagnosis of early acute renal allograft rejection.
  • Marsh et al[ used deep learning algorithms to evaluate intraoperative donor kidney biopsies with the aim of determining which kidneys were eligible for transplantation. The authors used CNNs as a deep learning algorithm. The primary advantage of CNN is that the models can automatically discover prominent features from the data alone, without requiring a set of handcrafted parameters and extensive input normalization.
  • Most recently, CNNs have been explored as primary tools for glomeruli detection Different models were shown to be able to differentiate image patches containing isolated normal glomeruli from non-glomerular structures. Marsh et altrained the network with a total of 870 sclerosed and 2997 non-sclerosed glomeruli that were labeled.
  • The images were acquired from hematoxylin and eosin (HE)-stained frozen wedge donor biopsies. The fully conventional model in the study showed a high correlation with percent global glomerulosclerosis (R2 = 0.828). The authors concluded that the performance of the CNN alone was equivalent to that of a board-certified clinical pathologist.
  • Liu et al examined the diagnosis of T-cell-mediated kidney rejection using a data feed acquired by RNA sequencing. The authors used three ML methods called linear discriminant analysis (LDA), SVM, and random forest (RF).
  • The molecular signature discovery data set involved five kidney transplant patients with T-cell-mediated rejection (TCMR) and five with stable renal function. The forecast models were tested on 703 biopsies with Affymetrix GeneChip expression profiles available in the public domain.
  • The LDA predicted TCMR in 55 of the 67 biopsies labeled TCMR, and 65 of the 105 biopsies designated as antibody-mediated rejection (ABMR). The RF and SVM models showed comparable performances. These data illustrated the feasibility of using RNA sequencing for molecular diagnosis of TCMR.
  • Halloran et al and Reeve et al used molecular microscopy techniques to evaluate allograft biopsies, including molecular phenotyping with platforms such as microarrays that measure the expression of thousands of genes. To express the likelihood that particular diseases are present in the biopsy, the authors developed the TCMR score and the ABMR score assigned by classifiers (using weighted equations) built by standard ML methods.
  • The authors also developed the Molecular Microscope Diagnostic System (MMDx) that assesses the TCMR and ABMR in a reference set of biopsy samples using ML-derived classifier algorithms. Archetypal analysis and an additional 12 ML methods (individually or in ensembles) were used during the development of the MMDx. Archetype analysis is a probabilistic data-driven unsupervised statistical approach that categorizes separate groups of patients (archetypes).
  • The ensembles made diagnoses that were both more accurate than the best individual classifiers and almost as stable as the best, in line with the previous studies from the ML literature. Human experts had about 93% agreement (balanced accuracy) signing out the reports, while RF-based automated sign-outs showed similar levels of agreement (92% and 94% for predicting the expert MMDx sign-outs for TCMR and ABMR, respectively).
  • In 451 biopsy samples where a feedback was obtained, clinicians indicated that the MMDx agreed more commonly with the clinical decision (87%) than histology (80%) (P = 0.0042). In another study, the same group of researchers explored the frequency of rejection in areas of interstitial fibrosis and tubular atrophy (i-IFTA) in kidney transplant biopsies by using histology Banff 2015 and an MMDx and concluded that i-IFTA in indication biopsies reflected current parenchymal injury, often with simultaneous ABMR but seldom with TCMR.
  • Hermsen et al used whole-slide images of stained kidney transplant biopsies to develop and validate a CNN for histologic analysis in renal tissue stained with periodic acid Schiff. The researchers assessed the segmentation performance for different tissue classes and found that the best-segmented class was “glomeruli”, followed by “tubuli combined” and “interstitium”. The network detected 92.7% of all glomeruli in nephrectomy samples, with 10.4% of false positives. The authors also suggested that the CNN may have utility for quantitative studies involving kidney histopathology across.
  • Aubert et al used archetype analysis to identify distinct groups of patients with transplant glomerulopathy. The researchers examined data from 552 biopsy samples taken from 385 patients with transplant glomerulopathy, using unsupervised archetypal analysis that integrated clinical, functional, immunologic, and histologic parameters.
  • The authors identified five archetypes with distinct clinical, histologic, and immunologic features, as well as different outcomes (kidney allograft survival rates). The authors suggested that their approach permitted to decrease patient heterogeneity and created meaningful groups in terms of morphologic patterns, disease activity/progression, and risk of failure.
  • Kim et al used a fully automated system using CNN to identify regions of interest and to detect C4d positive and negative peritubular capillaries in gigapixel immune-stained slides. The authors used deep-learning-assisted labeling to enhance the performance of the detection method. Using this approach, they were able to train the CNN with a small number of samples. They suggested that their system was highly reliable, efficient, and effective for the detection of renal allograft rejection.
  • Finally, Ligabue et al evaluated the role of a CNN as a support tool for kidney immunofluorescence reporting and found that CNNs were 117 times faster than human inspectors in analyzing 180 test images. The accuracy of the CNN was comparable with that of experienced pathologists in the field.

Graft survival

  • Simic-Ogrizovic et al used data from 27 patients and 33 variables to train an ANN to predict chronic rejection progression, and suggested that ANN seemed more reliable in the prediction of the chronic rejection course than the usual statistical methods.
  • Lin et al examined single time-point models (LR and single-output ANNs) vs multiple time-point models (Cox models and multiple-output ANNs) to predict kidney transplant outcomes. The authors concluded that single time-point and multiple time-point models can achieve comparable area under the curve (AUC), except for multiple-output ANNs, which may perform poorly when a large proportion of observations are censored. LR can achieve similar performance as ANNs if there are no strong interactions or non-linear relationships among the predictors and the outcomes.
  • Akl et al developed an ANN model to predict the 5-year graft survival in living-donor kidney transplants. Estimates from the validated ANNs were compared using Cox regression-based nomograms. Researchers used data from 1581 patients for training and 319 patients for validation. The positive predictive value of graft survival was 82.1% and 43.5% for the ANNs and Cox regression-based nomogram, respectively. The authors concluded that ANNs were more accurate and sensitive than the Cox regression-based nomogram in predicting 5-year graft survival.
  • Lofaro et al used two different classification trees to predict chronic allograft nephropathy (CAN) within 5 years after transplantation by evaluating 80 renal transplant patients’ routine blood and urine tests collected after 6 mo of follow-up, and concluded that the use of classification trees is an acceptable alternative to traditional statistical models, especially for the evaluation of interactions of risk factors.
  • Greco et al also used DTs to build predictive models of graft failure and retrospectively studied 194 renal transplant patients with 5 years of follow-up. The primary endpoint was graft loss within 5 years of follow-up. In the classification algorithm, the researchers studied the following parameters: Age, gender, time on dialysis, donor type, donor age, human leukocyte antigen (HLA) mismatches, delayed graft function (DGF), acute rejection episode, CAN, and body mass index and concluded that the use of DTs in clinical practice may be an acceptable alternative to the traditional statistical methods.
  • For the evaluation of the 3-year graft survival in kidney recipients with systemic lupus erythematosus (SLE), Tang et al applied classification trees, LR, and ANNs to the data describing kidney recipients with SLE retrieved from the United States Renal Data System database. The 95% confidence interval of the area under the receiver-operator characteristic curve (AUROC) was used to quantify the discrimination capacity of the prediction models. The authors concluded that the performance of LR and classification trees was not inferior to that of more complex ANN.
  • Yoo et al assessed the predictive power of ensemble learning algorithms [survival DT, bagging, RF, and ridge and least absolute shrinkage and selection operator (LASSO)] and compared their outcomes to those of the conventional models (DT and Cox regression) to predict graft survival in a retrospective analysis of the data from a multicenter cohort of 3117 kidney transplant recipients. By means of a survival DT model, the index of concordance was found as 0.80, with the episode of acute rejection during the 1-year post-transplant being associated with a 4.27-fold increase in the risk of graft failure. In conclusion, the authors reported that ML methods may provide flexible and practical tools for predicting graft survival.
  • In a cross-sectional study, Nematollahi et al examined the 5-year graft survival in 717 patients, using a multilayer perceptron of ANN (MLP-ANNs), LR, and SVMs to construct prediction models. The authors assessed the validity of the models using different evaluation tools such as AUC, accuracy, sensitivity, and specificity and concluded that the SVM and MLP-ANN models could efficiently be used for survival prediction in kidney transplant recipients.
  • Tapak et al compared the LR and ANN approaches to predict graft survival in their data set from a retrospective study of 378 patients. According to their analysis, the ANN model outperformed LR in the prediction of kidney transplantation failure. The ANN model showed a higher total accuracy (0.75 vs 0.55) and better area under the ROC curve (0.88 vs 0.75) when compared to LR.
  • Zhou et al assessed the association of 17 proteins with allograft rejection in a cohort of 47 patients. The researchers used the LASSO variable selection method to select the significant proteins that predict the hazard of allograft loss. Conventional model selection techniques accept the strategy of best subset selection or some of the stepwise variants.
  • Though, such a strategy is computationally unreasonable when the number of predictors is large. As demonstrated, the subset selection method may be numerically unstable, thus the developing model may suffer from poor prediction accuracy. As one of the most popular variable selection methods, LASSO is able to overcome the computational hurdle of the subset selection approach. The authors deduced that KIM-1 and VEGF-R2 had individual significant positive associations with the hazard of renal failure.
  • In a study conducted to predict the future values of estimated glomerular filtration rate (eGFR) for kidney recipients, Rashidi Khazaee at al developed and validated an ANN-based model (multilayer perceptron network) using three static covariates of the recipients’ gender and the donors’ age and gender, as well as 11 dynamic covariates of the recipients including current age, time since transplant, serum creatinine, fasting blood sugar, weight, and blood pressures available at each visit.
  • The development and validation datasets included 72.7% and 27.3% of the 25811 records from the historical visit data of 675 adult kidney recipients. The ANN-based model dynamically predicted a future eGFR value based on a number of fixed and time-dependent longitudinal data. The authors suggested that using such analytical tools may help in realizing the administration of personalized medicine in kidney transplantation.
  • In another study, Mark et al used an ensemble of methods including random survival forests constructed from conditional inference trees. The benefit of combining diverse models to predict kidney transplant survival is that different models may work better than others on different cohorts of the data. The dataset was provided by the United Network for Organ Sharing and consisted of recipients who had kidney transplant surgery in the United States from 1987 to 2014.
  • The authors used 73 variables of the 163199 observations available during the chosen 10-year time period and proposed that the model achieved a better performance than the estimated post-transplant survival model used in the kidney allocation system in the United States.
  • In a multicenter study, Raynaud et al analyzed 403497 eGFR measurements of 14132 patients using a number of different ML techniques and identified eight distinct eGFR trajectories with latent class mixed models. Using a validation cohort of 9992 individuals, the authors suggested that their results provided the base for a trajectory-based assessment of kidney transplant patients for risk stratification and monitoring.
  • In a critical paper, Bae et al examined whether ML techniques are superior to conventional regression analysis. Studying the records of 133431 adult deceased donor kidney transplant recipients from the national registry data, the authors randomly selected 70% of the transplant centers for training and 30% for validation.
  • They used different ML procedures (gradient boosting and RF) and regression analysis, with the aim of predicting DGF, 1-year acute rejection, death-censored graft failure, all-cause graft failure, and death in the training set. After comparing the performances of different models in the validation set, the authors asserted that ML does not outperform the conventional regression-based approaches in predicting various kidney transplant outcomes.

Optimizing the dose of immunosuppression

  • McMichael et al developed an intelligent dosing system for optimizing FK 506 therapy, and suggested that the computerized dosing algorithm for FK 506 is as an “expert system” using stochastic open loop control theory. They developed an AI dosing system (IDS) that would predict the drug dosages and levels.
  • This IDS was programmed with hundreds of dosing histories, i.e., previous dose, previous level, current dose, and current level. The system was then used as a model to develop an equation that relates the current FK 506 dose and level with the desired dose and level. The IDS calculates the FK 506 dose required to achieve the target level. A prospective validation study shown that the model was 95% accurate in describing the relationship between FK 506 dosage and FK 506 plasma level, and that there were no biases in the dosing predictions.
  • Camps-Valls et al used neural networks for personalizing the dosage of cyclosporine A (CyA) in patients who had undergone kidney transplantation. The researchers used three kinds of networks [multilayer perceptron, finite impulse response (FIR) network, and the Elman recurrent network] while the formation of neural-network ensembles was used in a scheme of two chained models where the blood concentration predicted by the first model constituted an input to the dosage prediction model.
  • After using 364 samples from 22 patients for training and 217 samples from 10 patients for testing, the authors decided that the best model was an ensemble of FIR and the Elman network. This model yielded an r value of 0.977 in the validation set. The authors also suggested that neural models have proven to be well suited to this problem not only because of the accuracy of their estimations but also because of their precision and robustness.
  • In Gören et al’s study, 654 CyA measurements and 20 input parameters from 138 patients were used to train (473 samples) and validate (181 samples) an adaptive-network-based fuzzy inference system. The model aimed at predicting CyA concentration based on 20 input parameters which included concurrent use of drugs, blood levels, sampling time, age, gender, and dosing intervals.
  • The authors measured the performance of the developed model using root-mean square error, which was calculated as 0.057 for the validation set. In conclusion, the researchers suggested that their model could effectively assist physicians in choosing the best therapeutic drug dose in the clinical setting.
  • In two consecutive papers, Seeling at al described the development of a computer-aided decision system for planning tacrolimus therapy and then the integration of this system to the hospital information system. The authors used data from 492 patients and 13053 examinations, and created a classification model (conditional inference trees) using patient profiles, associated distributions, and intervals of medication adaption (decrease, increase, or maintain).
  • The theoretical model resulted in 16 classes of patients and associated distributions, which were then translated to a medical logic module. Eventually, a method for determining semi-automated immunosuppressive therapy was created to guide nephrologists.
  • In their study where they used data from 1045 renal transplant patients, Tang et al utilized 80% of the randomly selected data to develop a dose prediction algorithm, and employed 20% of the data for validation. Multiple linear regression, ANN, regression tree (RT), multivariate adaptive regression splines, boosted RT, support vector regression, RF regression, lasso regression, and Bayesian additive RT were applied, and their performances were compared in this work.
  • Among all the ML models, RT performed best in both the derivation [0.71 (0.67-0.76)] and validation cohorts [0.73 (0.63-0.82)]. The authors suggested that the ML models used to predict the tacrolimus dose may facilitate the administration of personalized medicine.
  • In Thishya et al’s study, the ANN and LR models were used to predict the bioavailability of tacrolimus and the risk of post-transplant diabetes based on the ABCB1 and CYP3A5 genetic polymorphism status. Besides polymorphism, the authors used the age, gender, BMI, and creatinine data from 129 patients for the input layer of their ANN and concluded that the ANN and multifactor dimensionality reduction analysis models explored both the individual and synergistic effects of variables in modulating the bioavailability of tacrolimus and risk for post-transplant diabetes.

Diagnosis of rejection

  • Hummel et al examined 145 patients who had kidney biopsy for the differential diagnosis of nephrotoxicity and acute cellular rejection using 18 different clinical and laboratory values for the input parameters, including tacrolimus dose, serum creatinine, and histocompatibility, to train the ANN.
  • The classification results were considered significant by the experts who evaluated the classifiers. However, the researchers asserted that higher rates of sensitivity would be required to apply the classifier in clinical practice. In a separate paper, the same group of authors used the same database to examine the performance of different AI techniques to screen the need for biopsy among patients suspected of having nephrotoxicity or acute cellular rejection during the first year after transplantation.
  • They used the ANN, SVM, and Bayesian interference (BI) to indicate if the clinical course of the event suggested the need for biopsy. The technique that showed the best sensitivity value as an indicator for biopsy was the SVM with an AUC of 0.79. The authors suggested that this technique could be used in clinical practice.
  • In Metzger et al’s study, SVM-based classification was used for resection and non-rejection. The researchers examined 103 patients (39 for training and 64 for validation) with a kidney biopsy and used CE-MS-based urinary proteome analysis for the data feed. The application of the rejection model to the validation set resulted in an AUC value of 0.91. In total, 16 out of the 18 subclinical rejections and all 10 clinical rejections (BANFF grades Ia/Ib) and 28 of the 36 controls without rejection were correctly classified.
  • Pineda et al developed an integrative computational approach leveraging donor/recipient (D/R) exome sequencing and gene expression to predict the clinical post-transplant outcome. The authors made a statistical analysis of 28 D/R kidney transplant pairs with biopsy-proven clinical outcomes with rejection, identifying a significantly higher number of mismatched non-HLA variants in antibody mediated rejection (AMR).
  • They also identified 123 variants associated mainly with the risk of AMR and applied an ML technique to circumvent the issue of statistical power. Eventually, they found a subset of 65 variants using RF that predicted post-transplant AMR with a very low error rate.
  • In another study, the same group of authors evaluated 37 biopsy-paired peripheral blood samples from a cohort with stable kidney function with AMR and TCMR by RNA sequencing. The authors used ML tools to identify the gene signatures associated with rejection and found that 102 genes (63 coding genes and 39 noncoding genes) associated with AMR (54 upregulated), TCMR (23 upregulated), and stable kidney function (25 upregulated) perfectly clustered with each rejection phenotype and highly correlated with main histologic lesions (P = 0.91).
  • Their analysis identified a critical gene signature in peripheral blood samples from kidney transplant patients who underwent AMR, and this signature was sufficient to differentiate them from patients with TCMR and immunologically quiescent kidney allografts.
  • Wittenbrink et al used a pretransplant HLA antigen bead assay data set to predict the risk of post-transplant ACR risk. Employing an SVM-based algorithm to process and analyze the HLA data, the model achieved the prediction of 38 graft recipients who experienced ACR with an accuracy of 82.7%. The authors reported that this was one of the highest prediction accuracy rates in the literature for pre-transplant risk assessment of ACR.

Prediction of early graft function

  • Shoskes et al used retrospective data from 100 cadaveric transplants to train an ANN with the aim of predicting DGF. For input, the authors used donor and recipient characteristics and then validated the model in 20 prospective cadaveric transplants. In the validation cohort, the ANN was able to predict DGF with an 80% accuracy. The authors suggested that the use of such a model could help improve donor/recipient selection and perioperative immunosuppression and reduce overall costs.
  • In Brier et al’s study, the researchers used an ANN and LR to predict DGF. In the examination of 304 cadaveric kidney transplantations, the researchers used data from 198 patients for training and 106 patients for validation. The results of the study showed that LR analysis was more sensitive in predicting ‘no DGF’ (91 vs 70%), while the ANN predicted ‘DGF’ with a higher sensitivity (56% vs 37%). The neural network was 63.5% sensitive and 64.8% specific. In conclusion, the authors deduced that ANN may be used for prediction of DGF in cadaveric renal transplants.
  • Santori et al assessed the efficiency of a neural network model to forecast a delayed decrease of serum creatinine in pediatric kidney recipients. In this study, the neural network was constructed with a training set of 107 pediatric kidney recipients, using 20 input variables.
  • The model was validated in a second set of 41 patients. The overall accuracies of the neural network for the training set, the validation set, and the whole patient cohort were 89.1%, 76.92%, and 87.14% respectively. The developed ANN model had a higher sensitivity compared to LR analysis. The authors inferred that the neural network model could be used to predict a delayed decrease in serum creatinine among pediatric kidney recipients.
  • In another study, Decruyenaere et al constructed eight different ML methods to predict DGF and compared them to LR by using the data from 475 cadaveric kidney transplantations. Besides LR, the authors employed the following methods to construct the prediction models: LDA, quadratic discriminant analysis, and SVMs using linear, radial basis function and polynomial kernels, DT, RF, and stochastic gradient boosting.
  • The performance of the models was assessed by computing sensitivity, positive predictive value, and AUROC after a 10-fold-stratified cross-validation. The authors found that the linear SVM had the highest discriminative capacity (AUROC: 84.3%), outperforming each of other methods, except for the radial SVM, polynomial SVM, and LDA. However, it was the only method superior to LR. Eventually, the authors asserted that the linear SVM was the most appropriate ML method to predict DGF.
  • In Costa et al’s evaluation of the impact of donor maintenance-related (arterial blood gas pH, serum sodium, blood glucose, urine output, mean arterial pressure, vasopressors use, and reversed cardiac arrest) variables on the development of DGF, data from 443 cadaveric donors ML methods that included DT, neural network, and SVM to locate donor maintenance-related parameters that were predictive of DGF were used. However, according to the multivariable LR analysis, the donor maintenance-related variables did not have any impact on DGF occurrence.
  • In a large scale study, Kawakita et al aimed to build personalized prognostic models based on ML methods to predict DGF. Using the data obtained from the United Network for Organ Sharing/Organ Procurement and Transplantation Network, their development set included a total of 55044 patients and the validation set included 6176 patients. Of the selected 26 predictors, 13 were donor-related, eight were recipient-related, and five were transplant-related.
  • The authors used a development dataset with the selected features to train five ML algorithms: LR, elastic net, RF, extreme gradient boosting (XGB), and ANN. For performance comparison, a baseline model based on LR was developed. After training the ML algorithms, the authors assessed each model for three performance measures: Discrimination, calibration, and clinical utility using different metrics. All of the algorithms trained with the new predictors performed better or equally well in these characteristics compared to the baseline model, especially the ANN and XGB.
  • The XGB is an ensemble learning method, which assembles DT as its building blocks to build a strong learner that is able to learn the nonlinear relationships between the predictors and the outcome. The authors suggested that ML was a valid alternative approach for the prediction and identification of the predictors of DGF, adding an important piece of evidence to support the use of ML in driving medical progressions.

Other areas

  • In addition to the above-mentioned areas, AI techniques are used in kidney transplantation for different purposes.
  • We located different articles in the following topics: Assessment of risk for various complications such as cardiovascular risk, pneumonia, and CMV infection, prediction of changes in lipid parameters, prediction of HLA response, and assessment of the risk of kidney transplantation during the coronavirus disease 2019 pandemic.

CONCLUSION

  • AI is used in a large spectrum of studies in kidney transplantation, ranging from pathological evaluation to outcome predictions. Those studies pave the way for increased automation, which will increase standardization and speed in medical evaluations. CAD and quantifiable personalized predictions are developing at a great pace that will enhance precision medicine.
  • Robot Assisted Kidney Transplantation (RAKT) is a minimally invasive technique that uses robotic support to perform a kidney transplant. As a high level of expertise is required in kidney transplant and robotic surgery, RAKT is performed by transplant surgeons who have obtained extensive training and experience in robotics and transplant surgery.

What is robot assisted kidney transplantation?

  • Kidney Transplantation (KT) is the most preferred standard care of treatment for patients with end stage renal disease. Traditionally, kidney transplantation has been carried out by open surgery i.e by making large incisions. However, in the recent times, the procedure is being done with minimally invasive surgical procedures.
  • Robot Assisted Kidney Transplantation (RAKT) is a minimally invasive technique that uses a robotic support to perform the KT. As a high level of expertise is required in KT and robotic surgery, RAKT is performed by transplant surgeons with extensive training and experience in robotics and transplant surgery.

How does robot assisted kidney transplant surgery work?

The Technique:

  • Compared to conventional open kidney transplant surgery, a much smaller incision (about 7cm) is made in RAKT to remove the diseased kidney and insert the donor kidney into the abdomen., and then to stitch the blood vessels and the ureter. Another four or five small (0.5 to 1cm) incisions are used to insert the instruments into the abdomen.
  • One of the arms holds a high magnification 3D camera which is inserted into the abdomen through one of the key holes and provides a high-definition, magnified (12×), 3-D view of the surgical site. The other mechanical arms have surgical instruments attached to it that are designed to mimic the movement of the human hands and wrists.
  • The surgeon uses the console of the computer to manipulate the small surgical instruments that are more flexible and manoeuvrable as compared to the human hand.

What are the advantages of robotic kidney transplant surgery over open kidney transplant surgery?

The technical advantage of robotic kidney transplant surgery over open kidney transplant surgery

  • The robot replicates the surgeon’s hand movements, while minimizing hand tremors. The surgeon thus can not only make use of his/her experience and skills, but also operate with precision, dexterity and control in complex procedures.
  • Especially useful when the operative field is deep and narrow, and requires fine dissection and micro suturing.

Improved patient outcomes:

Robotic surgery in KT offers many benefits like:

  • Decreased chances of complications as compared to open surgery, especially in immunocompromised and end-stage renal disease patients undergoing KT.
  • Safer and more efficacious for obese patients who are otherwise not recommended for transplants.
  • Minimal invasive surgery helps in reduced
    • – blood loss
    • – hospital stays
    • – pain
    • – postoperative complication rate
    • – recovery time
    • – surgical scars

What is robot assisted surgery?

Robotic surgery, or robot-assisted surgery, is an advanced surgical procedure where small surgical tools are attached to a robotic arm that is controlled by a surgeon through a computer.

What are the risks of kidney transplant using robot assisted surgery?

Risks related to kidney transplants are drastically minimized with the robotic assistance. Still, possible risks that are specific to kidney transplant procedure include:

  • Damage to surrounding structures
  • Development of a hernia due to the small incisions made for the instruments, known as ‘port site hernia’
  • Twisting of the kidney (torsion) after the transplant
  • Scarring affecting the bowel in the long term (adhesive obstruction)
  • Trapping of carbon dioxide used during surgery in the abdomen
  • Nerve compression
  • Life threatening risks are miniscule.

What preparations are required before robotic kidney transplant surgery?

Before transplant instructions include:

  • Stop smoking or drinking
  • Lose any excess weight
  • Regular exercise
  • Vaccinations as advised
  • Dialysis before transplant
  • Necessary lab tests

What is the success rate of kidney transplant using robot assisted surgery?

The graft survival rate i.e the survival rate of the donor kidney is dependent on the inherent characteristics of the recipient’s body, hence there are no significant differences between the open surgery and robot assisted kidney transplant surgery. However, the robotic kidney transplant surgery offers significant benefits in terms of

  • Low surgical site infection (range 0-8%)
  • Incisional hernia rates (range 0-6%)
  • Improved aesthetic outcomes

What factors should be considered while choosing a hospital for robotic kidney transplant?

Since kidney transplant is a major surgery, it is important to ensure that the hospital has the infrastructure and trained team to support the pre-operative and post-operative needs. Certain factors to be considered are:

  • State-of-the-art robotic surgery, latest transplant technology and organ preservation facilities.
  • Expertise of the kidney transplant surgeons and his team. Specialized training in robotics, number of surgeries performed and success rate indicate the expertise of your surgeon.
  • Number and type of robotic kidney and other organ transplants that the center performs every year.
  • Transplant center’s organ donor and recipient survival rates.
  • Support services such as diagnostics, pharmacy, modular OT, ICU etc.

What factors govern the cost of robotic kidney transplant?

The cost of surgery usually depends on a multitude of factors, the primary ones being:

  • Experience and expertise of the kidney transplant surgeon and team.
  • Length of surgery and post surgical complications.
  • Underlying co-morbidities and age of the patient which may affect the – additional tests and medicine requirement.
  • Hospital stays – Room category availed; depending on the hospital’s billing policy.

To know more about robotic surgery and robotic kidney transplant, you can request for a call back and our robotic kidney transplant specialist will call you and answer all your queries.

References:
  • Robot-assisted kidney transplantation – pilot study. Available at https://www.guysandstthomas.nhs.uk/resources/patient-information/kidney/robotic-assisted-kidney-transplantation.pdf. Accessed on March 28, 2018

Advantages of Robotic Kidney Transplant Surgery over Open Kidney Transplant Surgery

Technical advantages:

  • The robot replicates the surgeon’s hand movements, while minimizing hand tremors. The surgeon thus can not only makes use of his/her experience and skills, but also operates with precision, dexterity and control in complex procedures.
  • Especially useful when the operative field is deep and narrow, and requires fine dissection and micro suturing.

Improved patient outcomes:

Robotic surgery in kidney transplant offers many benefits like:

  • Decreased chances of complications as compared to open surgery, especially in immunocompromised and end-stage renal disease patients undergoing kidney transplants.
  • Safer and more efficacious for obese patients who are otherwise not recommended for transplants.
  • Minimal invasive surgery helps in reduced – Blood loss, Hospital stays, Pain, Postoperative complication rate, Recovery time, Surgical scars.
  • Robot-assisted kidney transplantation (RAKT) has recently been introduced to reduce the morbidity of open kidney transplantation (KT). Robot-assisted surgery has been able to overcome many of the limitations of classical laparoscopy, certainly in complex and technically demanding procedures, such as vascular and ureteral anastomosis. Since the first RAKT in 2010, this technique has been standardized and evaluated in highly experienced robot and KT centers around the world.
  • In Europe, the European Association of Urology Robotic Urology Section (ERUS) created an RAKT working group in 2016 in order to prospectively follow the outcomes of RAKT. When performed by surgeons with both robotic and KT experience, RAKT has been proven to be safe and reproducible in selected cases and yield excellent graft function with a low complication rate. Multiple institutions have now adopted RAKT, and its use will likely increase in the near future.
  • However, structured training and proctoring will be mandatory for those embarking on RAKT in order to help them negotiate the learning curve and avoid technical mistakes. This chapter will describe RAKT from living and deceased donors and its application in kidney autotransplantation (KAT).

 

Living donor nephrectomy

  • Open donor nephrectomies were carried out for nearly 50 years until the introduction of laparoscopy in 1995 by Ratner et al. Since its first description in 1995, the laparoscopic approach for donor nephrectomy has demonstrated to improve peri- and postoperative outcomes such as blood loss, pain, hospital stay, as well as cosmetic results, when compared to open surgery.
  • In 2001, the first series of robot-assisted laparoscopic donor nephrectomy, using the da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA), was reported by the Group of the University of Illinois (Chicago). They demonstrated that robot-assisted nephrectomy is feasible, safe, and reproducible, providing similar results in comparison to the laparoscopic approach.
  • Nowadays, around 40% of all KT in the USA and around 20% of all KT in Europe are performed with living donors. Every year, the ratio of “emotionally related” living donors to genetically related living donors increases slightly, with most of the living donors currently being family members.
  • In comparison with KT from deceased donors, KT from living donors provides several advantages in terms of long-term patient survival, earlier graft function, longer graft survival, less aggressive immunosuppressive regimens, and reduced waiting lists.
  • When a living donor has two equally functioning kidneys, the left kidney is preferred for donation as the left renal vein is longer compared to the right renal vein. When the kidney function of both kidneys is different, the lesser functioning kidney is used for donation, in order to limit the risks for the donor.
  • Many concerns have been raised regarding the use of the right kidney for living donation, but literature suggests that right laparoscopic donor nephrectomy is feasible and results in good graft function.

2.1.2 Living donor kidney transplantation

  • RAKT has recently been introduced to reduce the morbidity of open KT. Since the first RAKT in 2010 by Giulianotti et al. in the USA, this technique has been standardized and evaluated in highly experienced robot and KT centers around the world. In 2014 Menon et al. standardized the technique with the transperitoneal approach and regional hypothermia known as the Vattikuti-Medanta technique.
  • The authors highlighted that RAKT is a safe technique with possible advantages such as low intra- and postoperative complications, better cosmetic results, and superlative vision that could result in better quality of the vascular and ureteral anastomoses. The first two European pure RAKTs were performed in July 2015 by Breda et al. and Doumerc et al..
  • In 2016, the European Association of Urology (EAU) formed the EAU Robotic Urology Section (ERUS) RAKT working group in order to prospectively follow the outcomes of RAKT. Breda et al. published the largest multicenter series of RAKT to date (120 patients).
  • Angelo Territo et al. addressed the functional results of RAKT from living donors at 1-year follow-up, and Vignolini et al. developed a RAKT program with grafts from deceased donors. Siena et al. described the technique for RAKT in grafts with multiple vessels. The feasibility of RAKT in children was described by the Ghent University group by Spinoit et al. 

2.2 Operative technique

2.2.1 Living donor nephrectomy

  • To date, several techniques are described for living donor nephrectomy, including open surgery, pure laparoscopy, hand-assisted laparoscopy, and robot-assisted surgery. The most commonly used technique is the minimally invasive transperitoneal laparoscopic approach. According to the literature, laparoscopic surgery for living donor nephrectomy achieves similar functional results compared to open and robot-assisted living donor nephrectomy, being equally safe for the donor.
  • Robot-assisted surgery offers clear advantages over conventional laparoscopy, thanks to the use of EndoWrist instruments, three-dimensional view, enhanced visualization of the operative field (12x), and, possibly, a shorter learning curve. Open nephrectomy for donation may offer an advantage in challenging cases such as grafts with multiple vessels and/or vascular anomalies and prior abdominal surgery. Furthermore, the open approach may be preferred in centers with low experience in laparoscopy and/or a low case volume of living donor nephrectomies .

Figure 1.

Trocar placement and patient positioning for nephrectomy during RAKT on living donors.

(A) Laparoscopically: patient positioned in lateral decubitus, linear port configuration along the pararectal line, with the camera placed at the most cephalic position (at the 12th rib level).

(B) Robot-assisted: patient positioned in lateral decubitus; GelPOINT device at the level of the ipsilateral fossa through a 6 cm Pfannenstiel incision; a 15-mm AirSeal trocar is placed in the device to introduce endovascular stapler and the 15-mm EndoCatch bag for organ extraction. An additional trocar is used to raise the kidney during the section of the vessels.

 

2.2.2 Back table preparation

  • After robot-assisted/laparoscopic living donor nephrectomy, the preparation of the kidney is performed at the back table close to the operating bed. First, the graft is placed in a basin with slushed ice and perfused with 1 liter of storage solution (Celsior®, or Custodiol®, or Institut Georges Lopez-1®).
  • Next, the graft vessels are carefully dissected. If the donor kidney has multiple arteries or veins, a vascular reconstruction can be performed. Siena et al. demonstrated that RAKT is possible using grafts with multiple vessels. The ureter can be pre-stented with a double-J if preferred. Subsequently, the kidney is wrapped in a gauze filled with slushed ice, with the artery and vein brought out through an opening in the gauze.
  • The aim is to keep the donor kidney at a constant low temperature after insertion in the abdominal cavity, until the vascular anastomoses are finished, and the kidney is reperfused. In addition, the gauze can prevent potential graft injury from manipulation with the robot arms. To keep the graft temperature below 20°C intracorporeally, ice is added through the GelPOINT® (Applied Medical, Rancho Santa Margarita, CA, USA) every 15 min.

Figure 2.

Preparation of the kidney graft after nephrectomy during RAKT from living donors.

(A) Ureteral double J stent is placed in the graft.

(B) A central hole in the gauze from which the artery and vein are outside.

(C and D) The graft is wrapped in a gauze jacket filled with ice slush.

2.2.3 Robot-assisted living donor kidney transplantation

2.2.3.1 Patient and trocar positioning

  • When using the da Vinci Si® or X® system, the patient is positioned in lithotomy position according to the Vattikuti-Medanta technique. When the da Vinci Xi® system is used, the patient is positioned in dorsal decubitus. A 20–30° Trendelenburg position is recommended. The required robotic instruments are monopolar scissors, Potts scissors, bipolar forceps, prograsp forceps, large needle driver, black diamond micro-forceps, and bulldog clamps.
  • A 12 mm camera port is inserted in the supra-umbilical area, and a pneumoperitoneum is created. Veres's needle puncture, optical trocar access, or the Hasson technique can also be used for access to the abdomen and creation of a pneumoperitoneum. The open approach (Hasson technique) has been reported to result in fewer complications. Three extra robotic 8 mm ports are placed under vision, and the robot is docked. Minimal changes in port placement are related according to the robotic system used.
  • A GelPOINT® device replaces the camera trocar through a 6–8 cm (four fingers) periumbilical incision once the transplant bed preparation has been performed. Alternatively, the GelPOINT® device can be introduced from the beginning through a 6–8 cm periumbilical incision, containing the camera and an assistant port.
  • This GelPOINT® device is used to introduce the graft in the abdominal cavity and allows for insertion of slushed ice (± 200 ml) via modified Toomey syringes into the abdominal cavity, surrounding the graft surface with the intent to achieve regional hypothermia (i.e., low constant temperature (<20°C) of the graft).
  • Additionally, GelPOINT® is a useful device for fast hand introduction if needed (i.e., in case of massive bleeding). In selected cases, the graft can be introduced transvaginal as described by few authors. The AirSeal® (Conmed, Utica, NY, USA) system might be used in order to maintain a stable and low-pressure pneumoperitoneum at 8 mmHg.

Figure 3.

Trocar placement and patient positioning for RAKT for Si/X/Xi in the right iliac fossa. Patient repositioned in dorsal decubitus, legs in Allen stirrups, table in 20–30° Trendelenburg; GelPOINT® device at the level of the umbilicus through a 6–8 cm vertical peri-umbilical incision; camera trocar and ice applicator in the GelPOINT® (eventually with 12 mm AirSeal® port); 3–8 mm robotic trocars in the lower abdomen, 2 in the left fossa and 1 in the right iliac fossa.

 

Figure 4.

Introduction of the kidney and ice through the Gel-POINT®.

(A) The GelPOINT® device is placed through a 6 cm (four fingers) incision.

(B) Ice slush is introduced in the abdominal cavity using modified Toomey syringes.

(C and D) The graft is introduced into the abdominal cavity.

(E and F) Once the graft is inside, Gel-POINT® cup is inserted to close the abdomen.

 

2.2.3.2 Transplant bed preparation

  • Accurate dissection of the external iliac vessels is performed. Subsequently, the bladder is prepared for ureteral reimplantation. A retroperitoneal pouch is created by incision of the peritoneum following a transverse line above the level of the appendix and mobilization of the peritoneal flaps.
  • These will be used to cover (retroperitonealize) the graft once the vascular anastomosis is completed. Although RAKT is a transperitoneal approach, retroperitonealization of the kidney is performed to avoid pedicle torsion and to enable future graft biopsies.

2.2.3.3 Venous and arterial anastomosis

  • After clamping of the external iliac vein with robotic bulldog clamps and the distal clamp followed by the proximal clamp, a longitudinal venotomy using cold scissors is performed. An end-to-side anastomosis between the graft renal vein and the external iliac vein is created, using a 6/0 Gore-Tex® CV-6 TTc-9 or THc-12 needle (W.L. Gore and Associates Inc., Flagstaff, AZ, USA) continuous suture. At the proximal angle, the suture is tied to secure the posterior wall of the anastomosis watertight and to avoid stenosis, and then the continuous suture is completed until the distal angle.
  • Prior to finishing the anastomosis, the lumen is flushed with heparinized solution using a 4.8 Fr ureteric catheter. The catheter may be pulled out by the assistant from outside the abdomen while the surgeon tightens the knot to secure the anastomosis. Next, the graft vein is clamped, and the bulldog clamps are removed from the external iliac vein and positioned on the external iliac artery, first proximally and then distally.
  • The artery may be incised with the cold scissors or a scalpel at the 1–2 o’clock position. Arteriotomy may be completed using a laparoscopic aortic punch to transform the linear arteriotomy into a circular one. In both arterial and venous anastomosis, the anastomosis is started by passing the needle in the external iliac vessel in an outside-inside direction and then inside-outside through the graft vessel. For the venous anastomosis, the knot is tied now, and the needle is then passed outside-inside through the renal vein to start the running suture.
  • For the arterial anastomosis, the suture is not tied yet (as for the venous anastomosis), and the needle is passed through the graft artery outside-inside before tying the suture to a loop that is left outside. This is done to prevent a difficult first needle passing in a small arterial lumen. After completing the arterial anastomosis, a clamp is positioned on the graft artery while the external iliac artery is declamped. If no sign of leakage (bleeding) is observed, the graft vein and artery are declamped.
  • The evaluation of the graft perfusion is primarily visual: pink colorization, a pulsatile graft artery, filling of the renal vein, and small bleedings from the renal capsule and urine output are signs of perfusion. Doppler ultrasound evaluation (drop-in ultrasound probe linked to TilePro™ function of the da Vinci Surgical System) is recommended to verify adequate perfusion of the graft.

Figure 5.

 

Overview of the main steps for venous anastomosis during RAKT from living donors.

(A) The graft renal vein is anastomosed in an end-to-side continuous fashion to the external iliac vein using a 6/0 Gore-Tex®.

(B and C) At cranial angle, the suture is knotted to fix the posterior wall of the anastomosis.

(D and E) The running suture is completed at the caudal angle.

(F) Before completing the anastomosis, the lumen is flushed with heparinized solution using a 4.8 Fr ureteral catheter.

 

Figure 6.

Overview of the main steps for arterial anastomosis during RAKT from living donors.

(A) The robotic scalpel is used to make a linear incision on the iliac artery, converting it in circular hole with a laparoscopic vascular punch.

(B) The running suture is carried out using a 6/0 Gore-Tex®; particularly in the caudal tying of an arterial anastomosis, the needle is passed in the external iliac vessel in an outside-inside direction, then outside-inside through the graft vessel.

(C and D) The running suture is completed at the caudal angle.

2.2.3.4 Ureteroneocystostomy

  • After flipping the kidney on the psoas and retroperitonealization of the graft, the ureteroneocystostomy is performed according to the Lich-Gregoire technique using a Monocryl or PDS 5/0 (Ethicon Inc., Cincinnati, OH, USA) continuous suture.
  • Care is taken to construct an adequate detrusor tunnel as anti-reflux mechanism. A double-J stent is inserted to protect the anastomosis. The stent can be removed after 3 weeks.

Figure 7.

Ureteroneocystostomy performed according to the Lich-Gregoir technique.

In (A) and (B) running suture between ureteral and bladder mucosa using 5-0 Monocryl.

In (C) and (D) the details of the anti-reflux tunnel.

2.3 Results

  • After reporting a single center experience on 17 cases of RAKT from living donation the European Experience in RAKT was published in 2018. One hundred twenty cases were prospectively collected in eight centers across Europe. The authors demonstrated the low complication rate (at 1 month follow-up) while maintaining excellent graft function (median eGFR at 30 days was 58 ml/min) and cosmetic results.
  • Three cases of graft loss due to arterial thrombosis during the first postoperative week were reported in these series (2.5%). This complication might be associated with technical errors during the learning curve. Territo et al. demonstrated that the functional results at 1-year follow-up were not statistically different from the functional results at 1-month follow-up.
  • The complication rate remained low. To date, there are no studies available comparing RAKT with the conventional open approach. However, an increasing body of evidence confirms that RAKT is at least non-inferior to open KT regarding both patient and graft survival.

Partial Nephrectomy

A partial nephrectomy is a surgery that fixes a kidney condition. The two types include an open partial nephrectomy and a robotic partial nephrectomy. A urologist will correct the condition and remove part of your kidney. They’ll also reconstruct your kidney. Most people fully recover within four to 12 weeks, depending on the procedure type.

What is a partial nephrectomy?

  • A partial nephrectomy is a type of surgery in which a surgeon removes part of your kidney to treat a disease or injury. Once your surgeon corrects the condition, they’ll reconstruct your kidney.
  • A surgeon’s goal during a partial nephrectomy is to remove the diseased or damaged part of your kidney while leaving as much healthy kidney tissue as possible. Maintaining kidney function is important because your kidneys are the main filters of your body, and they’re essential for life. Having two functioning kidneys helps your overall kidney function.
  • During a typical open partial nephrectomy, your healthcare provider will make one or more large cuts (incisions) in your abdomen. Your provider usually recommends this type of procedure if you have a large or invasive tumor on your kidney.
  • They may also perform the procedure laparoscopically. Laparoscopic surgery is less invasive than traditional open surgery. Your surgeon will make two to four small incisions in your abdomen of half an inch or less. They then insert a thin rod with a camera at the end (laparoscope) into one incision to see the inside of your body. They insert surgical tools into the other incisions.
  • You may be a candidate for a robotic partial nephrectomy if you have a small kidney tumor or if removing your entire kidney could result in kidney failure and the need for dialysis. A robotic partial nephrectomy is robotic-assisted surgery. Technology allows your provider to “pilot” the robot’s arms, letting them move much more precisely in hard-to-reach areas inside of your body. As a result, it’s much less invasive than an open partial nephrectomy.

How serious is a partial nephrectomy?

A partial nephrectomy is a major surgery. A surgeon will surgically access your kidney to fix a condition and restructure your kidney. Some surgery techniques are less invasive than others. Your surgeon is the best person to tell you which technique they recommend and why.

Who needs to have a partial nephrectomy?

A number of conditions may require a partial nephrectomy as treatment, including:

  • Kidney cancer.
  • Infection.
  • Damage from kidney stones.
  • Injury.
  • Birth defects.
  • High blood pressure as a result of blood supply problems to your kidneys.

PROCEDURE DETAILS

What happens before a partial nephrectomy?

  • Before a partial nephrectomy, you’ll meet with a healthcare provider. The provider will also discuss what type of partial nephrectomy procedure is best for you. You may have an open partial nephrectomy or a robotic partial nephrectomy.
  • They’ll check your general health. They’ll also take your vitals (temperature, pulse and blood pressure).
  • Tell your healthcare provider about any prescription or over-the-counter (OTC) medications you’re taking. These include herbal supplements. Aspirin, anti-inflammatory drugs, certain herbal supplements and blood thinners can increase your risk of bleeding. Be sure to check with your healthcare provider before stopping any medications.
  • Tell the healthcare provider about any allergies you have as well. Include all known allergies. These include medications, skin cleaners like iodine or isopropyl alcohol, latex and foods.
  • Your healthcare provider will also give you specific directions on eating and drinking before your partial nephrectomy. You shouldn’t eat or drink anything after midnight the night before your surgery. If you must take medications, you should take them with a small sip of water.
  • If you have a kidney tumor and it’s smaller than 1.5 inches (4 centimeters) in size, your provider will likely recommend a robotic partial nephrectomy. But if your tumor is between 1.5 inches and 2.8 inches (4 cm and 7 cm), your provider may still be able to treat it, depending on its location in your kidney.

What happens during a partial nephrectomy?

A special team of healthcare providers will perform a partial nephrectomy. The team typically includes:

  • Urologist.
  • Anesthesiologist.
  • Nurses.
  • The anesthesiologist will sedate you (put you under) with general anesthesia. You won’t be awake, won’t move and won’t feel any pain during the procedure. After you’re under, a provider will insert a urinary catheter. A urinary catheter is a small, flexible tube that drains urine (pee) from your bladder into a bag.
  • The procedure varies according to whether you have an open partial nephrectomy or a robotic partial nephrectomy.

Open partial nephrectomy

  • During an open partial nephrectomy, the urologist will use a sharp, sterile knife (scalpel) to carefully make an incision in your flank. Your flank is the fleshy part on the side of your torso, between your hip and your ribs. The incision may be as long as 12 inches (30 centimeters).
  • A large incision gives the urologist a clear look at your kidney. It also allows them to use their hands to correct the condition and reconstruct your kidney. The urologist will use a clamp to temporarily block blood vessels that transport blood into and out of your kidney. Then, they’ll use ice to cover your kidney. Ice lowers the temperature of your kidney, which slows the breakdown of tissue from lack of blood flow.

Robotic partial nephrectomy

  • During a robotic partial nephrectomy, the urologist will use a scalpel to make small incisions in your abdomen. The incisions are no bigger than about 3/4 of an inch (2 centimeters). They’ll insert a laparoscope (a thin rod with a camera) and the robotic surgical equipment into these small incisions.
  • Next, they’ll fill your abdominal cavity with carbon dioxide gas. The gas expands the area, giving the urologist enough space to move the surgical equipment and access your kidney. They’ll use the robot to stop blood flow to your kidney, correct your condition and reconstruct your kidney.
  • Once your urologist finishes reconstructing your kidney, they’ll use stitches and/or staples to close your incisions. They may stitch small silicone tubes (drainage tubes) in your incision sites. These drainage tubes remove blood or fluid from inside your body. They’re typically only in place for a few days.

How long does a partial nephrectomy take?

A partial nephrectomy usually takes three to four hours to perform.

What happens after a partial nephrectomy?

  • After a partial nephrectomy, a healthcare provider will cover your stitches with bandages. If you have a tumor, they’ll send it to a laboratory so researchers can examine it.
  • Your anesthesiologist will stop putting anesthesia into your body. Within a few minutes, you’ll be conscious (awake), but you’ll very likely still feel groggy.
  • You’ll then move to a recovery room, where providers will wait for you to wake up more fully and track your overall health. Once you wake up, healthcare providers will treat your pain. A robotic partial nephrectomy is less painful than an open partial nephrectomy. However, you’ll still need pain medication and management techniques.
  • Anesthesia very commonly causes nausea. If you have nausea, a provider will give you medication to treat it.
  • You must maintain a liquid diet for one to two days after surgery. A liquid diet helps give your body time to recover. As you heal and recover, providers will reintroduce you to solid foods.
  • The day after surgery, providers will encourage you to get out of bed and walk. Walking encourages healing, promotes blood flow and restores function to your affected areas. It also helps prevent blood clots in your legs, pneumonia and other complications.
  • After two days, a provider will remove your urinary catheter.
  • Once your healthcare providers determine you’re healthy enough and no longer require monitoring, they’ll discharge you to go home. A family member or friend must drive you home. It’s also a good idea to have a family member or friend help take care of you for at least a few days after the procedure, as you won’t be able to lift anything for at least several days.

How long is a hospital stay for a partial nephrectomy?

  • The typical hospital stay after a robotic partial nephrectomy is one to two days.
  • The typical hospital stay after an open partial nephrectomy is three to four days.

RISKS / BENEFITS

What are the advantages of a partial nephrectomy?

The primary advantage of a partial nephrectomy is that it corrects a condition that affects your kidneys. Some conditions, such as kidney cancer, are deadly without treatment. The risks of living with these conditions without treatment outweigh any risks associated with a partial nephrectomy in most people.

What are the risks or complications of a partial nephrectomy?

All surgical procedures have risks. Some risks of a partial nephrectomy include:

  • Anesthesia risks.
  • Healing problems.
  • Possible need for a blood transfusion.
  • Infection.
  • Mass of clotted blood (hematoma).
  • Blood clots.
  • Fluid buildup at surgical sites (seroma).

RECOVERY AND OUTLOOK

How long does it take to recover from a partial nephrectomy?

  • Your recovery depends on the type of partial nephrectomy, as well as your health history and any other conditions you have. Your healthcare provider is the best person to tell you the recovery timeline for your specific case.
  • Most people can resume normal activities eight to 12 weeks after an open partial nephrectomy. Recovery is faster after a robotic partial nephrectomy. Most people can resume normal activities four to six weeks after a robotic partial nephrectomy.

When can I go back to work?

  • You should be able to return to work about four weeks after a partial nephrectomy.
  • If you have a less physically demanding job, you may be able to return to work sooner.
  • If you have a more physically demanding job, it’s a good idea to schedule more time off.

WHEN TO CALL THE DOCTOR

When should I see my healthcare provider?

  • Schedule follow-up appointments with your healthcare provider. They’ll want to check your incisions and stitches. If you don’t have dissolvable stitches, they may remove your stitches after one to two weeks. If you have drainage tubes, they’ll remove those as well.
  • If your provider removed kidney cancer, they’ll also conduct tests to make sure your kidney cancer is gone. Most people get CT scans or other imaging tests at one month, 12 months and 24 months after their procedure to monitor their kidney health.
  • Contact your healthcare provider immediately if you experience any abnormal symptoms. Symptoms may include:
    • Blood in your urine (hematuria).
    • Heavy bleeding at your incision sites.
    • Discolored drainage from your incisions.
    • A fever of 100 degrees Fahrenheit (38 degrees Celsius) or higher.
    • Infection.
    • Bad odor around the surgical site.
    • Skin separation at your stitches.
    • Increased pain.

A note from Cleveland Clinic

  • A partial nephrectomy is a common and effective treatment for kidney cancer and other kidney conditions. There are two types of procedures: an open partial nephrectomy and a robotic partial nephrectomy. Your healthcare provider may recommend a robotic partial nephrectomy if you have a small tumor. However, some people may require an open procedure if they have a large tumor.
  • A partial nephrectomy is a common surgery, but it’s still a serious procedure. If you have any questions, reach out to your healthcare provider. They’re available to help and offer the best recommendations for your long-term health and quality of life.

Donor nephrectomy

Overview

  • A donor nephrectomy is a surgical procedure to remove a healthy kidney from a living donor for transplant into a person whose kidneys no longer function properly.
  • Living-donor kidney transplant is an alternative to deceased-donor kidney transplant. A living donor can donate one of his or her two kidneys, and the remaining kidney is able to perform the necessary functions.
  • The first successful organ transplant in the U.S. was made possible by a living kidney donor in 1954 and used open surgery for the kidney donation surgery. Currently, the vast majority of kidney donation surgeries are performed using minimally invasive laparoscopic techniques and may include the use of robot-assisted technology.
  • Living kidney donation via donor nephrectomy is the most common type of living-donor procedure. About 5,000 living kidney donations are performed each year in the U.S.

Why it's done

  • The kidneys are two bean-shaped organs located on each side of the spine just below the rib cage. Each one is about the size of a fist. The kidneys' main function is to filter and remove excess waste, minerals and fluid from the blood by producing urine.
  • People with end-stage kidney disease, also called end-stage renal disease, need to have waste removed from their bloodstream through a machine (hemodialysis) or with a procedure to filter the blood (peritoneal dialysis), or by having a kidney transplant.
  • A kidney transplant is usually the treatment of choice for kidney failure, compared with a lifetime on dialysis.
  • Living-donor kidney transplants offer several benefits to the recipient, including fewer complications and longer survival of the donor organ when compared with deceased-donor kidney transplants.
  • The use of donor nephrectomy for living kidney donation has increased in recent years as the number of people waiting for a kidney transplant has grown. The demand for donor kidneys far outnumbers the supply of deceased-donor kidneys, which makes living-donor kidney transplant an attractive option for people in need of a kidney transplant.

Types of live kidney donation

You may choose to donate your kidney in one of two ways:

  • Directed donation, in which you name a specific transplant recipient. This is the most common type of living-donor organ donation.
  • Nondirected donation, also known as good Samaritan or altruistic donation, in which you do not name the recipient of the donated organ. The match is based on medical need and compatibility.

If you and your intended recipient in a directed donation have incompatible blood types or are otherwise not a suitable match, paired-organ donation or donation chain programs may be an option.

  • Paired-organ donation. Two or more organ-recipient pairs trade donors so that each recipient gets an organ that is compatible with his or her blood type. A nondirected living donor also may participate in paired-organ donation to help match incompatible pairs.
  • Donation chain. More than one pair of incompatible living donors and recipients may be linked with a nondirected living donor to form a donation chain for compatible organs. In this scenario, multiple recipients benefit from a single nondirected living donor.

Risks

  • Donor nephrectomy carries certain risks associated with the surgery itself, the remaining organ function and the psychological aspects involved with donating an organ.
  • For the kidney recipient, the risk of transplant surgery is usually low because it is a potentially lifesaving procedure. But kidney donation surgery can expose a healthy person to the risk of and recovery from unnecessary major surgery.
  • Immediate, surgery-related risks of donor nephrectomy include:
    • Pain
    • Infection
    • Hernia
    • Bleeding and blood clots
    • Wound complications and, in rare cases, death
  • Living-donor kidney transplant is the most widely studied type of living organ donation, with more than 50 years of follow-up information. Overall, studies show that life expectancy for those who have donated a kidney is the same as that for similarly matched people who haven't donated.
  • Some studies suggest living kidney donors may have a slightly higher risk of kidney failure in the future when compared with the average risk of kidney failure in the general population. But the risk of kidney failure after donor nephrectomy is still low.
  • Specific long-term complications associated with living kidney donation include high blood pressure and elevated protein levels in urine (proteinuria).
  • Donating a kidney or any other organ may also cause mental health issues, such as symptoms of anxiety and depression. The donated kidney may fail in the recipient and cause feelings of regret, anger or resentment in the donor.
  • Overall, most living organ donors rate their experiences as positive.
  • To minimize the potential risks associated with donor nephrectomy, you'll have extensive testing and evaluation to ensure that you're eligible to donate.

How you prepare

Making an informed decision

  • The decision to donate a kidney is a personal one that deserves careful thought and consideration of both the serious risks and the benefits. Talk through your decision with your friends, family and other trusted advisers.
  • You should not feel pressured to donate, and you may change your mind at any point.
  • The Centers for Medicare & Medicaid Services and the Organ Procurement and Transplantation Network require that living-donor transplant centers provide an independent donor advocate to protect the informed consent process. This advocate is often a social worker or counselor who can help you discuss your feelings and answer any questions you have.
  • General criteria for kidney donation include:
    • Age 18 years or older
    • General good health
    • Two well-functioning kidneys
    • A willingness to donate
    • No history of high blood pressure, kidney disease, diabetes, certain cancers or major risk factors for heart disease
    • Completion of a thorough physical and psychological evaluation at the transplant center
  • If you meet the requirements to be a living donor, the transplant center is required to inform you of all aspects and potential results of organ donation and obtain your informed consent to the procedure.

Choosing a transplant center

  • Your physician or your living-donor kidney recipient's physician may recommend a transplant center for your donor nephrectomy.
  • You're also free to select a transplant center on your own or choose a center from your insurance company's list of preferred providers.
  • When considering a transplant center, you may want to:
    • Learn about the number and type of transplants the center performs each year
    • Ask about the transplant center's organ donor and recipient survival rates
    • Compare transplant center statistics through the database maintained by the Scientific Registry of Transplant Recipients
    • Assess the center's commitment to keeping up with the latest transplant technology and techniques, which indicates that the program is growing
    • Consider additional services provided by the transplant center, such as support groups, travel arrangements and referrals to other resources
    • Find out if the transplant center participates in paired-organ donation or donation chain programs

What you can expect

Before the procedure

  • Once you've gone through the living organ donor screening, evaluation and informed consent process, your donor nephrectomy procedure will be scheduled for the same day as the transplant surgery for the recipient.
  • Separate medical teams and surgeons typically perform the donor nephrectomy and the transplant surgery, but they work closely together.
  • You'll receive instructions about what to do the day before and the day of your kidney donation surgery. Make note of any questions you might have, such as:
    • When do I need to begin fasting?
    • Can I take my prescription medications?
    • If so, how soon before the surgery can I take a dose?
    • What nonprescription medications should I avoid?
    • When do I need to arrive at the hospital?

During the procedure

  • Donor nephrectomy is performed with general anesthesia. This means you will be asleep during the procedure, which usually lasts 2 to 3 hours. The surgical team monitors your heart rate, blood pressure and blood oxygen level throughout the procedure.
  • Surgeons almost always perform minimally invasive surgery to remove a living donor's kidney (laparoscopic nephrectomy) for a kidney transplant. Laparoscopic nephrectomy is associated with less scarring, less pain and a shorter recovery time than is open surgery to remove a kidney (open nephrectomy).
  • In a laparoscopic nephrectomy, the surgeon usually makes two or three small incisions in the abdomen. Very small incisions are used as portals (ports) to insert the fiber-optic surgical instruments. A slightly larger incision is used to remove the donor kidney. The equipment includes a small knife, clamps and a special camera called a laparoscope that is used to view the internal organs and guide the surgeon through the procedure.
  • In open nephrectomy, a 5- to 7-inch (13- to 18-centimeter) incision is made on the side of the chest and upper abdomen. A surgical instrument called a retractor is often used to spread the ribs to access the donor's kidney.

After the procedure

After your donor nephrectomy, you'll likely stay in the hospital for one or two days.

In addition, you can expect:

  • Care after your surgery. If you live far from your transplant center, your health care providers will likely recommend that you stay close to the center for a few days after you leave the hospital so that they can monitor your health and remaining kidney function.

     

  • You'll likely need to return to your transplant center for follow-up care, tests and monitoring several times after your surgery. Transplant centers are required to submit follow-up data at six months, 12 months and 24 months after donation. Your primary care provider may conduct your laboratory tests one and two years after your kidney surgery and send the information to the transplant center. Ongoing regular visits at least annually with your health care provider are recommended.

  • Recovery. Depending on your overall health, your health care providers will give you specific advice on how to take care of yourself and reduce the risk of complications during your recovery. This can include not sitting or lying in bed for long periods of time, not driving a car for 1 to 2 weeks, not lifting any objects heavier than 10 pounds (4.5 kilograms) for a month, caring for your incision, managing pain, and returning to your regular diet.
  • Return to typical activities. After kidney donation, most people are able to return to their regular daily activities after 2 to 4 weeks. You may be advised to avoid contact sports or other strenuous activities that may cause kidney damage.
  • Pregnancy. Kidney donation typically does not affect the ability to become pregnant or complete a safe pregnancy and childbirth. Some studies suggest that kidney donors may have a small increase in risk of pregnancy complications such as gestational diabetes, pregnancy-induced hypertension, preeclampsia and protein in the urine.

     

  • It's usually recommended that women wait at least six months to a year after donor nephrectomy before becoming pregnant. Discuss pregnancy plans with your health care provider.

Coping and Support

  • Becoming a living donor is a deeply personal decision that requires careful consideration of both the serious risks and the benefits. Reaching out to family members, friends, counselors, clergy or people who have gone through this process can be helpful.
  • Your transplant team also can assist you with useful resources and coping strategies throughout the kidney donation and donor nephrectomy process, such as:
    • Joining a support group for organ donors. Talking with others who have shared your experience can ease fears and anxiety.
    • Sharing your experiences on social media. Engaging with others who have had a similar experience may help you adjust to your changing situation.
    • Educating yourself. Learn as much as you can about your procedure and ask questions about things you don't understand. Knowledge is empowering.

Diet and nutrition

  • You should be able to go back to your regular diet soon after the kidney donation. Unless you have other health issues, you won't likely have any specific dietary restrictions related to your procedure.
  • Your transplant team includes a dietitian who can discuss your specific diet needs and questions with you.

Exercise

  • Maintaining a healthy lifestyle through diet and exercise is just as important for living kidney donors as it is for everyone else.
  • You can usually return to your typical physical activity levels within a few weeks or months after donor nephrectomy. It's important to talk with your health care provider before starting any new physical activity. Your transplant team can discuss your individual physical activity goals and needs with you.
  • Some health care providers recommend that living kidney donors protect their remaining kidney by avoiding contact sports, such as football, boxing, hockey, soccer, martial arts or wrestling, and wearing protective gear such as padded vests under clothing to protect the kidney from injury during sports.

 

Describe the ethical concerns and regulations of a kidney transplantation procedure.

  • Ethics refer to them as a set of “well-founded standards of right and wrong that prescribe what humans ought to do in terms of rights, obligations, benefits to society and fairness” (Spinoza, 2006, p. 12). Law on the other hand refers to a system of rules usually enforced by a set of institutions and used to regulate the behavior of individuals in a community or a country that recognizes such rules (Spinoza, 2006, p. 13).
  • Both ethics and law are important in guiding the behavior of medical practitioners to achieve better outcomes. This paper analyzes the ethical issues associated with organ transplantation and how such issues can be addressed within the framework of nursing ethics and law.

Organ Transplants

  • Organ transplantation is the act of “moving a body organ from one body to another or from a donor site in the patient’s own body, to replace the recipient’s damaged or absent organ” (Winters, 2000, p. 17). The organs that can be transplanted include the kidney, heart, eyes, and liver.
  • Organ transplantation is one of the breakthroughs in the field of medicine.
  • It has particularly helped in saving several lives which could have otherwise been lost due to organ failures. Despite its success, organ transplantation has been associated with serious ethical concerns which undermine its applicability. The main ethical concerns associated with it are as follows.

Procurement and Distribution of Organs

  • While organ transplantation has been widely accepted by doctors, patients, and even the law, the question of how to procure the organs legitimately and efficiently remains unaddressed. Besides, distributing the limited organs among the many patients is an ethical dilemma yet to be addressed.
  • The methods of obtaining the organs include donations by good Samaritans, paired exchange, deceased donors, and living donors (Winters, 2000, p. 45). Obtaining organs from deceased donors remains controversial because there has never been a consensus on the definition of death (Trung & Miller, 2008, p. 323).
  • Deceased donors are normally brain-dead (higher functions stops) even though their body organs could be kept alive through life support machines. However, some believe that brain-dead individuals are not completely dead. Thus it is not right to take their organs to benefit another patient. On the other hand, organs obtained from the body after all brain functions have stopped might not be helpful. Consequently, it will be very difficult to obtain organs from deceased donors if death is defined in terms of a situation where all brain functions have stopped.
  • Personal beliefs in terms of convictions considered to be true and a reflection of essential values about life and death have always been used in response to this ethical dilemma. Thus the definition of death in a particular community determines the procurement of organs. In some cases, the law is used to guide the process of procuring organs (Trung, The Ethics of Organ Donation by Living Donors, 2005, p. 125). However, what is lawful might not necessarily be ethical and this further complicates the process.
  • The distribution of organs is also an ethical dilemma as doctors find it difficult to determine who needs the organs most. Ideally, the organs should be distributed on a first-come-first-served basis. However, fair distribution of the organs has always been difficult due to personal interests, prejudice, and ethnocentrism associated with medical practitioners (Brezina, 2009, p. 57). To ensure distributive justice, the ethical principle of beneficence and justice should be upheld. Thus there should be fairness, equality as well as relativism regarding organ distribution.

Consent

  • According to the ethical principle of autonomy, the patient should be allowed to decide whether to undergo organ transplantation or not. In cases whereby the patient can not communicate, the decisions on organ transplantation have always been taken by the patient’s relatives.
  • To avoid the ethical dilemma on consent, some practitioners think that organ transplantation should be automatic unless the patient says no (Brezina, 2009, p. 65). Interest groups, however, oppose automatic transplants on the ground that it violates the patient’s constitutional right to make personal choices.

Payment for Organs and Transplantation Surgeries

  • Due to the short supply of organs, money has been used to regulate their demand and supply. Some individuals sell their organs to patients while hospitals curry out organ transplants only on patients who are willing and able to pay for the service.
  • The legality of selling organs remains controversial as some believe that it helps in increasing the supply of organs (Philips, 2004, p. 78). The sale of organs has also been opposed since it promotes organ trafficking and transplant tourism.
  • Besides, organ trafficking puts the recipients at risk of contracting diseases since the sellers usually avoid the organ screening process. While the law rejects the sale of organs, it might be unethical to let patients die for fear of breaking the law by buying organs.
  • According to the ethical principle of non-maleficence, the risks associated with the sale of organs can be reduced by regulating the process to benefit both the donor and the recipient of the organ (Philips, 2004, p. 79).

Socio-Economic Context

  • There has been debate on whether the limited organs should be given to individuals who contribute to their organ failures through irresponsible behavior such as alcoholism. Such individuals are normally stereotyped and discriminated against regarding organ transplantation (Kavanagh, 1991, p. 189).
  • The ethical principle of justice, however, calls for equal treatment for all patients irrespective of their socio-economic backgrounds.
 

Effectiveness of Organ Transplants

  • Organ transplantation is associated with the problem of organ rejection. Consequently, patients must take anti-rejection drugs for the rest of their lives to suppress their immune systems. However, this strategy makes the patients vulnerable to infections as their immune systems become suppressed (Ringos, 2011, p. 33).
  • Responding to this ethical dilemma calls for full disclosure of the consequences of organ transplants. The doctors must tell the patients all the possible negative consequences and benefits of organ transplants. The patient should then be able to make an informed decision regarding the transplant.

Conclusion

  • The above discussion indicates that ethics and law play an important role in enhancing better outcomes in the field of medicine. They not only guide the behavior of medical practitioners but also help in making decisions that determine the future of patients.
  • Even though organ transplantation is an accepted treatment method, its applicability is undermined by the ethical concerns surrounding it. Some of the ethical concerns associated with it include procurement and distribution of organs, consent, and paying for the organs (Brezina, 2009, p. 34). To address these ethical issues, it is important to observe the ethics and laws which govern the practice of medicine.

The ethics surrounding organ transplantation is a highly debated topic.  Although kidney transplantation has been around for many decades- shifting needs, cultural norms, and resource limitations have led to varying practices worldwide, bringing several ethical principles into the spotlight. Here, we will explore the ethical principles of the United Network for Organ Sharing (UNOS) of the US and examine the ethics of the kidney transplant practices of other countries.

In the US, the private, non-profit organization UNOS oversees the Organ Procurement and Transplantation Network (OPTN) that maintains a national registry for organ matching. The UNOS Ethics Committee defines three ethical principles:

  •     Utility: the maximization of net benefit to the community
  •     Justice: the fair pattern of distribution of benefits
  •     Respect for persons: respect for autonomy-  actions or practices respect independent choices made by individuals, as long as choices do not harm others

We will examine kidney transplant practices in 3 countries and how they embody these principles in different ways.

Iran—Utility

  • In the U.S., organ transplantation is altruistic and commercialization of organ donation is illegal.  A transplant team assesses the motives of the donor. With this model, there are currently over 95,000 people on the kidney transplant waiting list in the U.S.  In contrast, Iran developed a a program in 1988 that eliminated waiting list in a decade.
  • Iran’s kidney transplant program severely lagged behind their dialysis program. With very few kidney transplants being done, the Iranian Ministry of Health allowed patients on dialysis to receive transplants abroad with government funds. Between 1980-1985, more than 400 patients traveled to Europe and the U.S.
  • This was unsustainable, and by 1988- there was a large waiting list with no deceased-donor organ transplant program established.   Therefore, the Iranian government decided to create a government funded, regulated, and compensated living-unrelated donor kidney transplantation program.
  • In this model, if a patient has no living-related donors, they are referred to the Dialysis and Transplant Patients Association (DATPA) to be matched with a suitable living-unrelated donor. The DATPA has no brokers/outside agencies and all transplant teams belong to university hospitals. The government pays for hospital expenses and can subsidize the cost of immunosuppression. 
  • The donor receives an award and health insurance from the government.  Of note, foreigners are not allowed to undergo kidney transplantation from Iranian living-unrelated donors or allowed to volunteer as donors to Iranian patients.
  • This model is vastly different from the U.S., given heavy emphasis on the principle of utility. With a burgeoning waiting list, the Iranian government responded by increasing the utilization of available kidneys with financial compensation. Under this model, transplant candidates of low socioeconomic status have equal access to a potential kidney transplant.
  •  A study of 500 kidney transplant recipients and their living-unrelated donors in Iran revealed that 50.4% of recipients were low-income.  Also, 84% of paid kidney donors were poor , leading to concern with autonomy and coercion. There has also been a decrease in living-related donor transplants from nearly 100% in 1988 to 12% in 2005.  The Iranian model provides an interesting example of an alternative emphasis of the same three ethical principles.

South Africa—Justice

  • South Africa is unique being on the forefront of HIV+ organ donation. Dialysis is limited due to resources- available to the healthiest and most adherent patients. It is considered a bridge to transplantation (not chronic treatment), therefore, only patients suitable for kidney transplant are eligible for dialysis. Prior to 2008, since HIV+ patients were not considered candidates for transplant, they were also restricted from dialysis.
  • After June 2001, a multi-site clinical trial of HIV- organ transplantation into HIV+ patients. showed that there was no evidence of viral progression and no adverse effect on allograft function. Given higher HIV infection rates- HIV+ brain-dead donors are much more prevalent than in the United States. As a result, HIV+/HIV+ kidney transplants were adopted in South Africa in 2008.
  • Since then, 43 kidneys from 25 brain-dead donors have been transplanted at the University of Cape Town. Several factors have been tracked after transplant, including the incidence of donor-derived tuberculosis, resistance to anti-retroviral therapy, and recurrence of HIV-associated nephropathy (HIVAN). 
  • Recurrence of HIVAN has proven problematic, with two of the 43 patients losing their grafts due to recurrence and six with biopsies showing early HIVAN. This prompted research on the pathogenesis of recipient HIVAN and if donors with proteinuria or early HIVAN changes should be accepted. The study authors note that this risk of recurrence is an important consideration but may be worth the risk due to limited options for these patients.
  • This shifting paradigm in South Africa exemplifies an emphasis on utility and justice. The South African group is maximizing utility by tapping into a previously unused resource, HIV+ kidneys. However, justice, the fair pattern of distribution of benefits, is also being pursued by rigorously exploring a feasible treatment option for HIV+ ESKD patients. 
  • France is also tracking graft outcomes of HIV+/HIV+ kidney transplants.  HOPE in the US will track the clinical outcomes of 160 HIV+ kidney transplant recipients, where half will receive HIV+ kidneys and half HIV- kidneys. A better understanding of HIV+ organs and their transplantation outcomes will enable the world to maximize utility and promote transplantation for the HIV+ population.

Japan—Respect for Persons

  • Japan finds itself on another end of the spectrum as a developed country with one of the lowest organ transplant rates. According to the Global Observatory on Donation and Transplantation, in 2015 there were only 12.87 kidney donations in Japan per million inhabitants. In comparison, in the US, that number is 57.79 per million. Even though a technologically advanced and economically stable country, an understanding of the legal restrictions and cultural norms in Japan help explain why it lags behind in this respect.
  • One of the major causes for Japan’s historically low transplant numbers is the legal barrier to deceased organ transplant. Before 1997, deceased organ donations in Japan could only be made to family members and from people with cardiac death. This strict definition of death and restriction on eligible recipients kept transplant numbers low and promoted a reliance on living donors.
  • In 1988, the Japan Medical Association announced that it would accept brain death as human death but only if “the donor expressed in writing prior to death his/her intent to agree to donate his/her organs and agree to be submitted to an authorized brain death declaration, and his/her family members did not object to the donation.”
  • This turned out to be fairly stringent and did not have a major impact on transplantation rates. Under international pressure, another revision was made in 2010 to ease the rules over brain death such that even if an individual’s intent was unclear, donation of a brain-dead patient’s organs was possible with family consent. With this revision, legal barriers to deceased kidney transplant were greatly eased.
  • Despite these changes, cultural beliefs were slow to follow. Japan is largely a Buddhist and Shinto nation and in both traditions, a dead body should remain intact. In both national media and traditional texts, there is the belief that death is impure and an organ retrieved from a dead person is tainted. Even the Japan Organ Transplant Network (JOTN) states that brain death is only acknowledged as human death when a transplant is to be performed. There even exists a degree of reluctance among the medical community.
  •  This likely dates back to 1968 when Dr. Juro Wada carried out the first transplant from a brain-dead donor. He made the determination of brain death and performed the transplant operation himself. The recipient died three months after the operation and he was charged with murder. The charges were eventually dropped, but it triggered a long-running controversy over the definition of brain death and no transplants from brain-dead donors were carried out in Japan for the next three decades.
  • These cultural and, until recently, legal barriers necessitate that Japan rely heavily on living donor transplants. Living donor transplant rates have been increasing, now upwards of 90%, while deceased donor transplant rates have not changed since 2001. Returning to the three pillars of ethics, the current system in Japan is an example of their priority of respect for persons. Given low transplant numbers some may argue that it comes at the cost of utility and justice, however their strongly held beliefs and long-standing cultural norms place respect for autonomy at the forefront of their transplant discussions.

Conclusion

  • These international perspectives on kidney transplantation provide unique insight into the practices and consequences of different interpretations of the same three ethical principles. There are strengths and weaknesses to each, with challenges unique to each country given their history, resources, and cultures. 
  • The United States is no different, and expanding our worldview to explore and learn from other countries and their transplant programs may prove to be valuable as we navigate our own legal, ethical, and cultural hurdles in kidney transplantation.
  • . Find out and list the machine classifications and IEC 60601 standards applied to the equipment.

IEC 60601 medical electrical equipment classification

subclause IEC 60601 Medical Electrical Equipment Classification: FAQs

  • All clause references in this blog are to both IEC 60601-1:2005 (3rd edition) and IEC 60601-1:2005 (3rd edition) + Amendment 1:2012 , or the consolidated version IEC 60601-1:2012 ed. 3.1, but the actual text comes from edition 3.1.
  • *Note: ALL CAPITAL LETTERS identifies a defined term for the IEC 60601 series of standards within this blog.
  • What are the various classifications that are used in IEC 60601-1, edition 3.1? – The table at the beginning of this blog posting identifies the five parts of the Classification section. Each classification is described in more detail below.
  • Why do I need to classify my product for IEC 60601-1, 3rd ed.? – The standard says you have to classify “…ME EQUIPMENT, or parts thereof, including applied parts…” as noted in sub-clause 6.1. But a more practical reason you would want to classify your products that fall under the scope of IEC 60601-1  is it is a helpful tool in identifying the requirements that apply to the device and helps us in determining the test plan for the product to be tested.
  • What is an applied part? – The definition of an APPLIED PART is in sub-clause 3.8 of the standard. It states that an APPLIED PART is “part of ME EQUIPMENT that in NORMAL USE necessarily comes into physical contact with the PATIENT for ME EQUIPMENT or an ME SYSTEM to perform its function.” So, it can be a cable, lead, electrode, or many other parts of an ME EQUIPMENT, or an ME SYSTEM that is intended, by the manufacturer, in its NORMAL USE to come in contact with the PATIENT.
  • What are the classifications for Protection Against Electric Shock? –Two classifications fall under sub-clause 6.2 of the standard: 1) the power source, and 2) applied parts. Power sources can be an external power source and is either classified as a class I or class II ME EQUIPMENT or an internal power source, which is classified as INTERNALLY POWERED MEDICAL EQUIPMENT.
  • Power Sources – External Class I, External Class II, or Internal – Class I provides its protection against electric shock by having an additional safety ground (known as PROTECTIVELY EARTHED) that is connected to the internal and/or external conductive parts (metal) of the power source. Class II provides its protection against electric shock by having an additional layer of insulation beyond that of BASIC INSULATION (a single layer of insulation) and is provided either by DOUBLE INSULATION (two layers of insulation) or by REINFORCED INSULATION (the same as for DOUBLE INSULATION, but as one insulation system that is twice as thick, typically). An internal power source is usually a battery.
  • Applied Parts – B, BF, CF (also defibrillation-proof) – The second classification for protection against electric shock is for APPLIED PARTS. APPLIED PARTS are classified in one of six ways, and a product can have more than one type of APPLIED PARTS. The classifications for applied parts are type B, BF, or CF. Each of these three classifications can be DEFIBRILLATION-PROOF APPLIED PARTS for a total of 6 classifications. There are six separate symbols for these APPLIED PARTS, and they are noted in the table below, which comes from Table D.1 of Annex D of the standard.

symbols IEC 60601 Medical Electrical Equipment Classification: FAQs

  • Why do we have classifications for protection against electric shock? – Protection against electrical shock is important because electric shock is one of the main areas of concern in most electrical safety standards as the shock hazard can cause harm to the OPERATOR or PATIENT or even death. The main reason is we want to protect the PATIENT, who may have a depressed immune system from getting an electric shock that could injure or potentially kill the PATIENT. The depressed immune system makes them more likely to be harmed by an electric shock. We also want to consider the OPERATOR of the device, but they should not have a depressed immune system, so the worst-case to consider is the PATIENT.
  • What are the classifications for protection against harmful ingress of water or particulate matter? – There is a wide variety of these classifications (per sub-clause 6.3 of IEC 60601-1), and they are based on the standard IEC 60529 titled “Degrees of protection provided by enclosures (IP Code).” The IP Codes range from IP00 to IP68, which means respectively no protection against contact and ingress of objects along with not being protected against liquid ingress (IP00) to No ingress of dust; complete protection against contact along with protected against the effects of continuous immersion in water (IP68).  Table D.3, 2nd row (copied below), in the IEC 60601-1 standard details all the classifications in a summary list.
  • Why do we have classifications for protection against harmful ingress of water or particulate matter? – The reason we want to protect the ENCLOSURES of the device is to protect against ingress of these items (liquids and particulates), so they reduce the possibility of causing a hazard, such as a short based on bridging the electronics of the device causing potentially a fire hazard, a shock hazard, a thermal hazard, or other potential hazards.
  • What are the classifications for methods of sterilization? – For any part of the ME EQUIPMENT or its parts intended to be sterilized needs to be classified per the requirements of sub-clause 6.4. Classifications are based on the types of sterilization methods used in the medical device industry currently such as ethylene oxide (EtO), irradiation by gamma radiation, and moist heat by autoclave. The standard also mentions “…other methods validated and described by the MANUFACTURER.” Classification of sterilization methods is critical because each sterilization method presents unique environmental conditions that can adversely affect the ME EQUIPMENT. For example, EtO Sterilization frequently includes a vacuum cycle which may not be suitable for embedded batteries.
  • Why do we have a classification for suitability in an oxygen-rich environment? – The RISK of fire in an OXYGEN RICH ENVIRONMENT is considered to exist when a source of ignition is in contact with ignitable material (i.e., flammable materials) and there is no barrier (i.e., a solid enclosure) to prevent the spread of fire.
  • What are the classifications for modes of operation? – There are two modes of operation described in IEC 60601-1, edition 3.1: 1) CONTINUOUS OPERATION, and 2) non-CONTINUOUS OPERATIONS. When a device is classified as non-CONTINUOUS OPERATION, there is some type of duty cycle involved, so the device is rated properly. A duty cycle means the device is rated to be on for a certain period of time and off for a certain period of time. Many times the duty cycle is required, so a device may pass the EXCESSIVE temperatures in the ME EQUIPMENT test in sub-clauses 11.1.1 & 11.1.2 so as not to exceed the limits of the test requirements